Loading company
NextCure, Inc.
NXTC · Nasdaq · ·
Next earnings: November 4, 2026
$4.90-3.8%Sep 29 close
- 1M
- -19.6%
- 6M
- -50.6%
- 1Y
- -16.5%
- 5Y
- -94.1%
NXTC · Nasdaq · ·
Next earnings: November 4, 2026
$4.90-3.8%Sep 29 close
NextCure, Inc. is scheduled to report next on November 4, 2026. The date comes from Nasdaq’s earnings calendar, and companies sometimes move it.
The quarter ending December 31, 2020, against the same quarter a year earlier.
| Measure | 3 months toDec 31, 2020 | 3 months toDec 31, 2019 | Change |
|---|---|---|---|
| Total Revenue | $0.00 | $2M | -100.00% |
| Profit | -$14.9M | -$26.8M | +44.45% |
| Profit per share | -$2.80 | -$11.29 | +75.20% |
| Free Cash Flow | -$6.9M | -$10.7M | +35.08% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Releases land after the close or before the open, so the move is the session that follows.
SIM0505 is an investigational antibody-drug conjugate (ADC) targeting CDH6 and incorporating a proprietary topoisomerase I inhibitor payload. On July 14, 2026, the Company announced it had informed all U.S. clinical trial sites to stop screening, consenting, and enrolling new patients and that it no longer intends to expand the clinical site footprint. The Company is seeking opportunities to preserve the value of SIM0505 for our shareholders.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from NextCure, Inc.’s Item 2.02 8-K filed August 6, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
NextCure, Inc. has no earnings call transcript available.